Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]TJ0113 in Healthy Chinese Subjects
NCT06832540Phase 1Completed
- Sponsor
- Phecda Medicine
- Start
- Feb 2025
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TJ0113, sponsored by Phecda Medicine. Primary endpoints: Excretion ratio of total radioactivity at each time interval and cumulative recovery of total radioactivity in urine and feces at 240 hours, Maximum plasma concentration of total radioactivity at 168 hours and 4 more. Started Feb 2025; status: completed.
02
Drugs
TJ0113
Beyond the preview
Go deeper on NCT06832540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832540.